2020
Daptomycin perioperative prophylaxis for the prevention of vancomycin‐resistant Enterococcus infection in colonized liver transplant recipients
Sarwar S, Koff A, Malinis M, Azar MM. Daptomycin perioperative prophylaxis for the prevention of vancomycin‐resistant Enterococcus infection in colonized liver transplant recipients. Transplant Infectious Disease 2020, 22: e13280. PMID: 32216015, DOI: 10.1111/tid.13280.Peer-Reviewed Original ResearchConceptsLiver transplant recipientsDays of LTVRE infectionTransplant recipientsPerioperative prophylaxisRisk factorsLT periodVancomycin-resistant enterococcus infectionAntibiotic prophylaxis regimenDays post-LTAcute cellular rejectionPrimary graft failureLiver transplantation recipientsRenal replacement therapyRetrospective chart reviewIntensive care unitMultiple risk factorsVancomycin-resistant EnterococcusCellular rejectionLT morbidityPost-LTPre-LTProphylaxis regimenCause mortalityVRE bacteremia
2018
The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities
Cortesi P, Belli L, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, Cesana G, Duvoux C, Mantovani L, Strazzabosco M, Association T. The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities. Journal Of Viral Hepatitis 2018, 25: 791-801. PMID: 29406608, DOI: 10.1111/jvh.12877.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaDCC patientsTreatment strategiesIntestine Transplant AssociationProgression of HCVTransplant-eligible patientsHepatitis C therapyTransplant-related factorsCohort of patientsTime of transplantationDecision analytical modelCost-effectiveness analysisDAA effectivenessDAA treatmentEuropean LiverHCC presencePre-LTMELD scoreC therapyCirrhotic patientsDisease recurrenceTransplant centersSpecific regimenTransplant AssociationPatient level
2016
Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis
Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis. Alimentary Pharmacology & Therapeutics 2016, 44: 1090-1101. PMID: 27640785, DOI: 10.1111/apt.13798.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsBenzimidazolesCarcinoma, HepatocellularCost-Benefit AnalysisDisease ProgressionDrug Therapy, CombinationFluorenesGenotypeHepacivirusHepatitis CHumansLiver CirrhosisLiver NeoplasmsLiver TransplantationNeoplasm Recurrence, LocalQuality-Adjusted Life YearsRibavirinSofosbuvirUnited StatesConceptsHepatitis C virusLiver transplantationTime of transplantHCV recurrencePost-LTCost-effective strategyTreatment of HCVEnd-stage liver disease (MELD) scoreOptimal timingDonor LT recipientsLiver Disease scoreHCV genotype 1Hepatitis C therapyMarkov state transition modelHepatocellular carcinoma casesBase-case analysisSeparate treatment strategiesCost-effectiveness analysisAllograft failureDecompensated diseaseOngoing viraemiaPre-LTHCV treatmentLT recipientsMELD score
2005
40 THE NATURAL HISTORY OF CRYPTOGENIC CIRRHOSIS FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION: A HISTORICAL COHORT STUDY
Abdelmalek M, Mudaliar K, Liu C, Reed A, Nelson D, Asal N, Stacpoole P. 40 THE NATURAL HISTORY OF CRYPTOGENIC CIRRHOSIS FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION: A HISTORICAL COHORT STUDY. Journal Of Investigative Medicine 2005, 53: s393. DOI: 10.2310/6650.2005.00205.39.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseLiver transplantationCryptogenic cirrhosisSteatosis gradeClinical dataMean age 53Repeat liver transplantationYr post-LTFatty liver diseaseInsulin resistance syndromeCardiovascular disease deathsPost-LTPre-LTMELD scoreGlycemic controlHDL cholesterolLiver biopsyInflammatory activityLDL cholesterolLiver diseaseDisease deathsResistance syndromeSingle pathologistClinicopathologic correlationRisk factors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply